Sep 9, 2026 earnings call — Commercial deployment progress and Korean restructuring
Company recorded a $40.7 million impairment, contributing to a GAAP net loss of $55.5 million for Q2 2026.
Revenue $0.0B (est $0.0B) · EPS $-0.79 (est $-0.16)
Key quotes
"Most importantly, we are increasingly leveraging commercial partners with established relationships and workflow in the imaging space to meaningfully enhance our presence in the U.S."
"It is encouraging that we are already seeing reimbursement from insurers and payers with paid claims in the range of $200 to $700 per claim."
"The estimated annualized cost savings from these steps are expected to be approximately $2 million beginning in 2027."
Analyst Q&A 2
impairment, share count and system placements
Q (Jeffrey Cohen · Ladenburg Thalmann & Co.): He asked what impairment to expect for the rest of 2026 and the latest pro forma outstanding share count. He also asked how many systems were placed last quarter and the pipeline for the rest of the year.
A: Management said the impairment review has been completed as of today and they will continue periodic assessments under accounting rules but currently have no visibility on further impairments. They said the pro forma share count is about 70.06 million. They listed recent placements and said systems were placed in Greece, Romania, Czech Republic, with other units pending import licenses or installed in various U.S. settings and the Nanox Imaging Network.
"So since the latest update, we have placed systems in Greece, in Romania, in Czech Republic." — Erez Meltzer (CEO·CHAIR)
sales timing, cost savings, and reimbursement timing
Q (Scott Henry · AGP): He asked when the recent progress will translate into revenue, specifically how Q3 compares to Q2 and when revenue traction should appear. He also asked where the $2 million 2027 cost savings will show up, how much operating expense can be reduced, and timing for CMS reimbursement developments.
A: Management said the middle of the year was a reflection point and the impact of recent progress should appear in the next few months, with the Nanox Imaging Network pipeline converting to installations or sales. They said most of the $2 million savings will be reflected in operating expenses, some in COGS, and declined to give a specific figure now, saying they will announce numbers when available. On reimbursement, they said the reimbursement is already done and is already generating revenue, and they expect further impact in the very near future as more systems and sites are added.
"In terms of the reimbursement, first of all, it's already done, so we have already revenue which is generated from this reimbursement." — Erez Meltzer (CEO·CHAIR)